Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is organized by Practice Point Communications (PPC).

Launch Date: April 7, 2021
Release Date: March 1, 2021
Expiration Date: March 31, 2022

Description:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

CTEPH is defined as PH in the presence of an organized thrombus within the pulmonary vascular bed that persists at least 3 months after the onset of anticoagulant therapy. The most commonly reported symptoms of CTEPH include exercise intolerance, fatigue, and dyspnea. Symptoms experienced by CTEPH patients are non-specific and often similar to those of other more common diseases, so CTEPH is under diagnosed and often misdiagnosed as another disease. CTEPH is potentially curable only with pulmonary endarterectomy (PEA) surgery, which is the treatment choice for patients who are surgical candidates. For patients who are not surgical candidates or who have persistent/recurrent CTEPH after PEA surgery, there is an approved medical therapy or percutaneous balloon pulmonary angioplasty (BPA). This slide kit covers diagnosis and emerging treatment strategies including sequencing and combination therapy.

Additional details will be posted as soon as information is available.